JP2024516843A - 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 - Google Patents

抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 Download PDF

Info

Publication number
JP2024516843A
JP2024516843A JP2023568081A JP2023568081A JP2024516843A JP 2024516843 A JP2024516843 A JP 2024516843A JP 2023568081 A JP2023568081 A JP 2023568081A JP 2023568081 A JP2023568081 A JP 2023568081A JP 2024516843 A JP2024516843 A JP 2024516843A
Authority
JP
Japan
Prior art keywords
antigen
amino acid
binding region
seq
multispecific molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516843A5 (https=
Inventor
ダン・シッダールタ・チャンド
ザーラ・ジャワド
オルガ・イグナトヴィッチ
ニコラ・アン・ラムゼイ
スペンサー・キャンベル
ベス・ウェンズリー
エマニュエル・シリル・パスカル・ブライエンド
ケー・マーク・ブシェル
ベンジャミン・マキシム・モーリン
ヴェロニカ・フランチスカ・イルコウ
Original Assignee
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2024516843A publication Critical patent/JP2024516843A/ja
Publication of JP2024516843A5 publication Critical patent/JP2024516843A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023568081A 2021-05-04 2022-05-04 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 Pending JP2024516843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
US63/201,537 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024516843A true JP2024516843A (ja) 2024-04-17
JP2024516843A5 JP2024516843A5 (https=) 2025-05-14

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568081A Pending JP2024516843A (ja) 2021-05-04 2022-05-04 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法

Country Status (16)

Country Link
US (2) US11718669B2 (https=)
EP (1) EP4333893A4 (https=)
JP (1) JP2024516843A (https=)
KR (1) KR20240006054A (https=)
CN (1) CN117425494A (https=)
AR (1) AR125753A1 (https=)
AU (1) AU2022271331A1 (https=)
BR (1) BR112023022319A2 (https=)
CA (1) CA3217289A1 (https=)
CL (1) CL2023003244A1 (https=)
CO (1) CO2023016037A2 (https=)
IL (1) IL308157A (https=)
MX (1) MX2023013078A (https=)
PE (1) PE20240369A1 (https=)
TW (1) TW202304965A (https=)
WO (1) WO2022236276A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2025188697A1 (en) * 2024-03-04 2025-09-12 Agenus Inc. Methods of treating cancer using anti-cd96/anti-tigit antibodies and combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2020132034A1 (en) * 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
CA2896058A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
KR20250024106A (ko) 2013-08-22 2025-02-18 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3169363A4 (en) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Methods of treating cancer using tigit inhibitors and anti-cancer agents
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
WO2017023749A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN108290936B (zh) 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
PE20181046A1 (es) * 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
JP6821688B2 (ja) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
WO2017218970A1 (en) 2016-06-17 2017-12-21 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3589313A4 (en) 2017-02-28 2021-05-19 Seagen Inc. ANTI-TIGITE ANTIBODY
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
KR102770786B1 (ko) 2017-05-02 2025-02-20 머크 샤프 앤드 돔 엘엘씨 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
KR20200073203A (ko) 2017-08-11 2020-06-23 블링크 바이오메디컬 에스아에스 면역조절인자로서의 ｃｄ96-결합제
JP7317272B2 (ja) 2017-09-29 2023-07-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
CN110914304B (zh) 2017-11-10 2022-07-26 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TWI877769B (zh) 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
AU2019207296A1 (en) 2018-01-15 2020-07-16 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
EP3746119A4 (en) 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
KR102224556B1 (ko) 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
CN111836831A (zh) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CN120441704A (zh) * 2019-06-26 2025-08-08 圆祥生技股份有限公司 T细胞活化抗体
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
CA3217279A1 (en) * 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2020132034A1 (en) * 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2022236276A2 (en) 2022-11-10
CN117425494A (zh) 2024-01-19
PE20240369A1 (es) 2024-03-04
CO2023016037A2 (es) 2023-11-30
TW202304965A (zh) 2023-02-01
BR112023022319A2 (pt) 2024-02-20
US20230014036A1 (en) 2023-01-19
US11718669B2 (en) 2023-08-08
US20240141039A1 (en) 2024-05-02
CA3217289A1 (en) 2022-11-10
AU2022271331A1 (en) 2023-10-26
CL2023003244A1 (es) 2024-04-19
EP4333893A2 (en) 2024-03-13
KR20240006054A (ko) 2024-01-12
AU2022271331A9 (en) 2023-11-09
IL308157A (en) 2024-01-01
EP4333893A4 (en) 2025-06-18
US12479913B2 (en) 2025-11-25
AR125753A1 (es) 2023-08-09
WO2022236276A3 (en) 2023-01-19
MX2023013078A (es) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7395554B2 (ja) 抗ｃｔｌａ－４抗体およびそれらの使用方法
JP7369233B2 (ja) 抗ｌａｇ－３抗体及びその使用方法
KR102629972B1 (ko) 항-cd137 항체 및 이의 사용 방법
JP2023083455A (ja) 抗ｔｉｍ－３抗体及びその使用方法
US11680098B2 (en) Antibodies that specifically bind human CD96
US12479913B2 (en) Polynucleotide encoding anti-TIGIT and anti-CD96 antibodies
US20220389095A1 (en) Anti-tigit antibodies and methods of use thereof
US20250109201A1 (en) Anti-ilt2 antibodies and uses thereof
HK40076263A (en) Anti-cd96 antibodies and methods of use thereof
EA043100B1 (ru) Антитела против tim-3 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310